A Prospective, Open-label, Non-randomized, Naturalistic, Long-term Safety Surveillance, Observational Study of Either Ciprofloxacin (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) or a Non-quinolone Antibiotic (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) in the Treatment of Pediatric Patients With Infectious Diagnoses
Latest Information Update: 04 Aug 2015
At a glance
- Drugs Ciprofloxacin (Primary) ; Ciprofloxacin (Primary) ; Antibacterials
- Indications Bacterial infections; Paediatric infections
- Focus Adverse reactions
- Acronyms QUIP
- Sponsors Bayer
- 18 Apr 2009 Actual patient number (1029) added as reported by ClinicalTrials.gov.
- 18 Apr 2009 Actual initiation date changed from Apr 2000 to Oct 1999 as reported by ClinicalTrials.gov.
- 16 Oct 2008 New trial record.